The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?
 
Andrea Phillips Sitlinger
No Relationships to Disclose
 
Peter A. Ubel
Consulting or Advisory Role - Humana
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Charlene Wong
No Relationships to Disclose
 
Rishi Sachdev
No Relationships to Disclose
 
David Anderson
No Relationships to Disclose
 
Yousuf Zafar
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Consulting or Advisory Role - AIM Specialty Health; Family Reach Foundation; Vivor
Research Funding - AstraZeneca (Inst)